Amylyx Pharmaceuticals Discontinues ORION Program for AMX0035 in Progressive Supranuclear Palsy After Phase 2b Results
I'm PortAI, I can summarize articles.
Amylyx Pharmaceuticals Inc. has decided to discontinue the ORION program for AMX0035 in progressive supranuclear palsy (PSP) after Phase 2b trial results showed no significant differences from placebo. The drug was well-tolerated, and the company will now focus on the Phase 3 LUCIDITY trial of avexitide, with enrollment expected to conclude in 2025. Additionally, Amylyx is advancing AMX0035 in Wolfram syndrome and AMX0114 in ALS, with early Phase 1 LUMINA trial data expected in 2025.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments